How close are dual and triple incretin drugs to being used in everyday medicine?
These drugs are already here for treatment, but not yet for prevention. Single GLP-1 receptor agonists like semaglutide are already approved for type 2 diabetes and obesity, and dual agonists like tirzepatide (a GIP/GLP-1 co-agonist) are approved for the same conditions [1][3]. Triple agonists like retatrutide are in advanced clinical trials, with phase 2 data showing they can produce weight loss that rivals bariatric surgery [5]. However, the leap from treating established disease to preventing it in healthy or at-risk populations requires long-term safety and cost-effectiveness data that is still being gathered. The 2024 review by Alfaris et al. notes that these agents represent 'the future direction of incretin-based therapy,' but they are not yet standard preventive tools [1].
What can these drugs actually achieve for weight, blood sugar, and liver health?
The evidence shows a clear step-up in effectiveness as you move from single to dual to triple agonists. For weight loss, triple agonists like retatrutide have demonstrated 'the highest achievable weight loss with pharmacotherapy,' with some trials showing over 15% reduction in body weight [3]. This is a game-changer because even a 5-10% weight loss can prevent or reverse type 2 diabetes and fatty liver disease. For blood sugar control, dual agonists like tirzepatide lower HbA1c (a measure of average blood sugar) more effectively than single GLP-1 drugs, with fewer gastrointestinal side effects [3]. For liver health, a 2024 review in Gut highlights that dual and triple agonists are showing 'histological improvements in MASLD/MASH' (fatty liver disease) in phase 2 trials, which is a major step toward preventing cirrhosis [2]. The 2023 review by Newsome and Ambery agrees, but cautions that it is unclear whether these benefits come directly from the drugs or indirectly from weight loss [4].
What are the catches and uncertainties that still need to be resolved?
Despite the promise, several key questions remain unanswered. First, the optimal balance of hormones in these multi-agonists is not settled: for GIP, it is still debated whether agonism or antagonism is better [4]. Second, side effects add up: combining GLP-1, GIP, and glucagon actions may increase nausea, vomiting, and other gastrointestinal issues, and the 2023 review warns that 'the potential improvement in efficacy will need to be weighed against the cumulative side-effect burden' [4]. Third, cost and access are major barriers—these are expensive biologic drugs, and their use in preventive medicine would require health systems to justify the expense for people who are not yet sick. Finally, the 2024 review by Gutgesell et al. points out that 'further research is needed to fully understand how these therapies exert their effect on body weight,' especially the gut-brain communication pathways [5]. So while the drugs are powerful, they are not yet a simple plug-and-play solution for prevention.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2023 to 2025, 4 from 2024 or later, 3 in Q1 journals, collectively cited 355 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 40 papers retrieved from a database of over 500 million.
Sources used in this answer
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review
This 2024 narrative review confirms that GLP-1 receptor agonists are effective for blood glucose control, weight loss, and cardiovascular protection, and positions dual and triple agonists as the next frontier in incretin-based therapy for type 2 diabetes and obesity.
Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists
This 2024 review in Gut reports that dual and triple incretin agonists are showing histological improvements in fatty liver disease (MASLD/MASH) in phase 2 trials, making them a promising treatment option, especially for patients with coexisting obesity or diabetes.
Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare
This 2025 review highlights that triple agonists like retatrutide achieve the highest weight loss of any pharmacotherapy (over 15% reduction), and that dual agonists like tirzepatide have fewer gastrointestinal side effects than single GLP-1 drugs.
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
This 2023 review notes that while GLP-1 and combination agonists improve weight, insulin resistance, and liver parameters in MASH, it remains unclear whether these effects are direct or secondary to weight loss, and cautions that side effects, drug interactions, and optimal hormone ratios are unresolved.
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
This 2024 review states that triple GIPR:GLP-1R:GCGR agonists rival the efficacy of bariatric surgery in preclinical and clinical trials, but emphasizes that more research is needed on mechanisms of action and gut-brain communication to achieve sustained weight loss without adverse effects.